Clinical trial
Bosentan in Digital Ulcers
NCT00319696 · Actelion, Industry · Completed
Key facts
| NCT number | NCT00319696 |
|---|---|
| Title | Bosentan in Digital Ulcers |
| Official title | Long-term Bosentan Open Label Extension of the AC-052-331 Study in Systemic Sclerosis Patients With Ischemic Digital Ulcers |
| Acronym | RAPIDS 2 OL |
| Lead sponsor | Actelion, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Digital Ulcers |
| Intervention type | Drug |
| Interventions | Bosentan 62.5 mg, Bosentan 125 mg |
| Enrollment | 116 |
| Start date | Jul 8, 2004 |
| Primary completion | Jan 22, 2009 |
| Completion | Jan 22, 2009 |
| First posted | Apr 27, 2006 |
| Last update posted | Feb 4, 2025 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: